Ertumaxomab (ertu), another mAb, is designed to form a tri-cell complex with HER2/neu+ tumor cells, CD3+ T cells, and accessory cells in order to potentiate direct, and immune-mediated anti-tumor responses [91]. The gene discussed is ERBB2; the disease is neoplasm.